Product Information
CHLORDIAZEPOXIDE-CLIDINIUM CAP is a generic product labeled by Alembic Pharmaceuticals Inc., priced at $0.2561 per EA under NDC 62332074431. Its NADAC has been published 137 times since Feb 21, 2024.
FDA first approved this application on Sep 15, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5; 2.5 mg/1; mg/1
Manufacturer
Alembic Pharmaceuticals Inc.NDC
62332074431
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDEApproval Type
Generic (ANDA)
FDA Application
ANDA216969FDA Approved
9/15/2023
TE Code
AB
On Market Since
10/4/2023
Pharmacological Classes
Price Statistics
The NADAC for CHLORDIAZEPOXIDE-CLIDINIUM CAP has been published 137 times since Feb 21, 2024, and over the history we have for it it has declined 31.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2561 per EA |
|---|---|
| All-time high | $0.5272 (Oct 16, 2024) |
| All-time low | $0.2405 (Mar 18, 2026) |
| 52-week high | $0.3051 |
| 52-week low | $0.2405 |
| Median price | $0.2844 |
| Average price | $0.3038 |
| Largest weekly change | +78.0% (Aug 21, 2024) |
| Weeks tracked | 137 |
| Tracking since | Feb 21, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Chlordiazepoxide hydrochloride and clidinium bromide market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Alembic Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Chlordiazepoxide hydrochloride and clidinium bromide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anticholinergic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CHLORDIAZEPOXIDE-CLIDINIUM CAP?
The current National Average Drug Acquisition Cost (NADAC) for CHLORDIAZEPOXIDE-CLIDINIUM CAP, manufactured by Alembic Pharmaceuticals Inc., is $0.2561 per EA (NDC 62332074431), effective Sep 30, 2026.
How has the price of CHLORDIAZEPOXIDE-CLIDINIUM CAP changed over time?
Over the history we have for it, the NADAC for CHLORDIAZEPOXIDE-CLIDINIUM CAP has declined 31.4%. It has been tracked across 137 weekly CMS publications since Feb 21, 2024.
What are the highest and lowest recorded NADAC prices for CHLORDIAZEPOXIDE-CLIDINIUM CAP?
Since Feb 21, 2024, the NADAC for CHLORDIAZEPOXIDE-CLIDINIUM CAP has ranged from a low of $0.2405 (Mar 18, 2026) to a high of $0.5272 (Oct 16, 2024), with a median of $0.2844 per EA.
Are there cheaper alternatives to CHLORDIAZEPOXIDE-CLIDINIUM CAP?
No other NADAC-published product currently shares the active ingredient and strength of CHLORDIAZEPOXIDE-CLIDINIUM CAP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CHLORDIAZEPOXIDE-CLIDINIUM CAP?
CHLORDIAZEPOXIDE-CLIDINIUM CAP (NDC 62332074431) is labeled by Alembic Pharmaceuticals Inc., and CMS classifies it as a generic product.